SILDENAFIL DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Sildenafil Drug Market, By Drug Type (Branded Drugs, Generic Drugs, Over The Counter Drugs), By Indication (Erectile Dysfunction, Pulmonary Arterial Hypertension, Benign Prostatic Hyperplasia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Dosage Form (Tablets, Oral Jellies, Injections,, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East)

Recent Developments:

New product launches:

In August 16, 2023, Mangoceuticals, Inc., a healthcare company, launched its second Mango ED product, which combines the active ingredient in Viagra, sildenafil, with the company's original compound. Interested customers can choose between the company’s original Tadalafil-based Mango ED solution and a sildenafil-based Mango ED product through its telemedicine platform.
In June 22, 2023, CMP Pharma, a pharmaceutical company, launched Liqrev, the first U.S. FDA-approved ready-made oral liquid of sildenafil. The drug is intended to treat pulmonary arterial hypertension in people who are unable of swallowing tablets.
In October 2022, Zydus Group, a pharmaceutical company, announced that it has received final approval from the U.S. Food and Drug Administration (FDA) to market sildenafil for oral suspension USP 10 mg/ml. Sildenafil for oral suspension is used to treat pulmonary hypertension.
In September 2019, Lupin, a pharmaceutical company, launched sildenafil tablets USP, 25 mg, 50 mg, and 100 mg, having received an approval from the U.S. Food and Drug Administration.

Acquisition and partnerships:

In October 2022, Pfizer Inc., a pharmaceutical company, Roman, an digital healthcare clinic for men, announced a supply agreement to offer Roman members access to the only U.S. FDA approved authorized generic version of Viagra (sildenafil citrate).